Impact of probiotic supplementation on mortality of induced 1,2-dimethylhydrazine carcinogenesis in a mouse model.
ABSTRACT Probiotic bacterial strains have been increasingly used in clinical practice as many health benefits result from their use. However, severe side effects such as bacteremia and fungemia have been reported in inmunocompromised patients and those with chronic disease.
The purpose of this study was to report the impact of probiotic supplementation on the mortality of mice undergoing carcinogenesis induction with 1,2-dimethylhydrazine (DMH).
Two treatment protocols were used. In experiment 1, Lactobacillus delbrueckii UFV-H2b20, Bifidobacterium animalis var. lactis Bb12, and Saccharomyces boulardii were added to the drinking water, to control mice and those undergoing injections of DMH daily. Probiotic supplementation was started 1 wk before and continued throughout the 6 wk of DMH injections. In experiment 2, the same probiotics were administered daily, except on the first day that DMH was administered. The mortality of these animals was recorded. Bacterial translocation was determined in mice in experiment 1.
Groups with DMH-induced injury treated with lactobacilli, bifidobacteria, and the mixture of lactobacilli and bifidobacteria presented with 40%, 30%, and 60% mortality, respectively. Death happened mainly between 48 h and 72 h after the first injection of DMH. On the other hand, no mice in experiment 2 died during the study period. Bacteria were found to be translocated to mesenteric lymph nodes, spleen, and liver.
Supplementation of L. delbrueckii UFV-H2b20 and B. animalis var. lactis Bb12 in mice with DMH-induced injury led to death in some animals. The results suggest that increased bacterial translocation was probably related to mortality. These findings are an alert to the potentially severe side effects associated with the use of probiotics under extremely stressful situations.
- [Show abstract] [Hide abstract]
ABSTRACT: Colorectal cancer (CRC) is the third most common form of human cancer. Diverse therapies such as surgery and chemotherapy have shown excellent results in CRC. However, they still have limitations. There is a need to develop new CRC treatment strategies. Probiotic formulations have shown excellent promises in CRC as modest, preventive and early stage therapeutics. This review summarizes the recent development of probiotics in CRC and highlights the importance of the intestinal microbiota balance in CRC, cover current research on probiotics for CRC prevention and treatment with emphasis on the mechanisms involved. Specifically, this report describes evidences on the role of probiotics in inhibiting tumor progression, in reducing oxidative stress, in reducing colon cell DNA damage, in producing anti-cancer compounds, in improving the microflora balance, in stimulating the host immune response and in other physiochemical conditions of the gut. Even though, some of these effects were observed in several human trials when probiotics formulations were used as a supplement with CRC therapies, the application of probiotics as a biotherapeutic against CRC still needs further investigations.Journal of Medical Microbiology 04/2013; · 2.30 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: PURPOSE: To determine the effect of probiotics on the development of chemically induced (1, 2-dimethylhydrazine) colonic preneoplastic lesions, in mice. METHODS: The animals were divided into five groups. The control group was injected with carcinogen alone and the other groups also received probiotics (1- Lactobacillus delbrueckii UFV-H2b20; 2- Bifidobacterium animalis var. lactis Bb12; 3- L. delbrueckii UFV-H2b20 plus B. animalis var. lactis Bb12; and 4- Saccharomyces boulardii) administered orally in drinking water throughout fourteen weeks. RESULTS: Consumption of lactobacilli and bifidobacteria alone resulted in a significant reduction of the total number of aberrant crypt foci (55.7% and 45.1%, respectively). Significant reduction in the number of these small foci (<3 aberrant crypts) was only observed in the group treated with lactobacilli (52.2%) in comparison to control group. The number of larger foci (>3 aberrant crypts) crypts had no significant reduction. CONCLUSION: L. delbrueckii UFV-H2b20 and B. animalis var. lactis Bb12 administered alone protect colonic preneoplastic lesions in mice, while the combined treatment of these bacteria and the administration of S.boulardii were not effective in reducing such colonic lesions.Acta cirurgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 05/2013; 28(5):367-372. · 0.48 Impact Factor